Patricia Penovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Patricia Penovich has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- James W. Wheless
Le Bonheur Children's Hospital Memphis Tennessee USA
8 shared publications - Adrian L. Rabinowicz
Neurelis, Inc., San Diego, USA
5 shared publications - Enrique Carrazana
Neurelis, Inc., San Diego, USA
5 shared publications - Joseph I. Sirven
Department of Neurology, Mayo Clinic, Scottsdale, USA
4 shared publications - Danielle A. Becker
The Ohio State University Wexner Medical Center
3 shared publications - Janice M. Buelow
Epilepsy Foundation Landover MD United States
3 shared publications
Latest Publications
- 21 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e213520
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
- 21 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e213520
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
- 4 October 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 172, 110746
Pre-treatment seizures and cognition at the time of focal epilepsy diagnosis
- 4 October 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 172, 110746
Pre-treatment seizures and cognition at the time of focal epilepsy diagnosis
- Open Access
- 7 August 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110644
Immediate-use rescue medication and the epilepsy monitoring unit: experiences from an expert panel
- 7 August 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 171, 110644
Open AccessImmediate-use rescue medication and the epilepsy monitoring unit: experiences from an expert panel
- Open Access
- 16 April 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (1) , 34-42
Do Seizures Damage the Brain ?—Cumulative Effects of Seizures and Epilepsy: A 2025 Perspective
In 1885, William Gowers proposed that epilepsy is a progressive disease, based on clinical evidence before any effective treatments were available. His long-standing hypothesis has been summarized with the statement “seizures beget seizures.” Whether this is the case and related questions about seizure-induced modification and damage of brain circuits are of fundamental importance for neurobiological understanding of epilepsy, development of effective treatment strategies, clinical management, and prognostication. Consensus about progression and seizure-induced damage has remained controversial. Here, we critically review these long-standing questions, incorporating perspectives about perceived inconsistencies in past studies, potential implications of recent longitudinal imaging and cognitive studies, and emphasize experimental and clinical gaps that have proved challenging. Answers to these questions are important for development of management strategies to achieve prompt effective acute control of seizures and prevention of their potential recurrence and long-term comorbidities.
- 16 April 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (1) , 34-42
Open AccessDo Seizures Damage the Brain ?—Cumulative Effects of Seizures and Epilepsy: A 2025 Perspective
In 1885, William Gowers proposed that epilepsy is a progressive disease, based on clinical evidence before any effective treatments were available. His long-standing hypothesis has been summarized with the statement “seizures beget seizures.” Whether this is the case and related questions about seizure-induced modification and damage of brain circuits are of fundamental importance for neurobiological understanding of epilepsy, development of effective treatment strategies, clinical management, and prognostication. Consensus about progression and seizure-induced damage has remained controversial. Here, we critically review these long-standing questions, incorporating perspectives about perceived inconsistencies in past studies, potential implications of recent longitudinal imaging and cognitive studies, and emphasize experimental and clinical gaps that have proved challenging. Answers to these questions are important for development of management strategies to achieve prompt effective acute control of seizures and prevention of their potential recurrence and long-term comorbidities.
- Open Access
- 28 June 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 24 (8) , 303-314
Short-Term Impact of Seizures and Mitigation Opportunities
Purpose of Review: The burden of epilepsy is complex and consists of elements directly related to acute seizures as well as those associated with living with a chronic neurologic disorder. The purpose of this systematic review was to characterize short-term burdens of seizures and to explore the potential value of acute treatments to mitigate these burdens apart from reducing the risk of status epilepticus. Recent Findings: A systematic literature search was conducted using PubMed to identify articles published from January 1, 2017, to June 22, 2023, that described short-term burdens and acute treatments of seizures. Primary outcomes included those related to short-term burdens of seizures and the benefits of acute treatments to reduce short-term burdens. Of the 1332 articles identified through PubMed and 17 through other sources, 27 had relevant outcomes and were included in the qualitative synthesis. Seizure emergencies negatively affected short-term quality of life and the ability to conduct normal daily living activities and were associated with physical (injury) and financial (emergency transport, hospitalization) burdens. The use of acute treatment was associated with a rapid return (≤ 1 h) to normal function/self for both patients and caregivers and potentially lower healthcare utilization and costs. Seizure action plans may improve knowledge and comfort with seizure care, empowering patients and caregivers. Summary: The short-term burden of seizures can create a substantial negative impact on patients and caregivers. Acute treatments may reduce the short-term burdens of seizures in addition to their well-described role to reduce seizure activity and the risk for status epilepticus.
- 28 June 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 24 (8) , 303-314
Open AccessShort-Term Impact of Seizures and Mitigation Opportunities
Purpose of Review: The burden of epilepsy is complex and consists of elements directly related to acute seizures as well as those associated with living with a chronic neurologic disorder. The purpose of this systematic review was to characterize short-term burdens of seizures and to explore the potential value of acute treatments to mitigate these burdens apart from reducing the risk of status epilepticus. Recent Findings: A systematic literature search was conducted using PubMed to identify articles published from January 1, 2017, to June 22, 2023, that described short-term burdens and acute treatments of seizures. Primary outcomes included those related to short-term burdens of seizures and the benefits of acute treatments to reduce short-term burdens. Of the 1332 articles identified through PubMed and 17 through other sources, 27 had relevant outcomes and were included in the qualitative synthesis. Seizure emergencies negatively affected short-term quality of life and the ability to conduct normal daily living activities and were associated with physical (injury) and financial (emergency transport, hospitalization) burdens. The use of acute treatment was associated with a rapid return (≤ 1 h) to normal function/self for both patients and caregivers and potentially lower healthcare utilization and costs. Seizure action plans may improve knowledge and comfort with seizure care, empowering patients and caregivers. Summary: The short-term burden of seizures can create a substantial negative impact on patients and caregivers. Acute treatments may reduce the short-term burdens of seizures in addition to their well-described role to reduce seizure activity and the risk for status epilepticus.
- Open Access
- 15 February 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (2) , 125-140
Benzodiazepines for the Treatment of Seizure Clusters
Patients with epilepsy may experience seizure clusters, which are described by the US Food and Drug Administration (FDA) as intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern. Untreated seizure clusters may increase the risk for status epilepticus, as well as decrease quality of life and increase burden on patients and care partners. Benzodiazepine therapies are the mainstay for acute treatment of seizure clusters and are often administered by nonmedical care partners outside a healthcare facility. Three rescue therapies are currently FDA-approved for this indication, with diazepam rectal gel being the first in 1997, for patients aged ≥ 2 years. Limitations of rectal administration (e.g., positioning and disrobing the patient, which may affect ease of use and social acceptability; interpatient variation in bioavailability) led to the investigation of the potential for nasal administration as an alternative. Midazolam nasal spray (MDS) was approved by the FDA in 2019 for patients aged ≥ 12 years and diazepam nasal spray (DNS) in 2020 for patients aged ≥ 6 years; these two intranasal therapies have differences in their formulations [e.g., organic solvents (MDS) vs. Intravail and vitamin E for absorption and solubility (DNS)], effectiveness (e.g., proportion of seizure clusters requiring only one dose), and safety profiles. In clinical studies, the proportion of seizure clusters for which only one dose of medication was used varied between the three approved rescue therapies with the highest single-dose rate for any time period for DNS; however, although studies for all three preparations enrolled patients with highly intractable epilepsy, inclusion and exclusion criteria varied, so the three cannot be directly compared. Treatments that have been used off-label for seizure clusters in the USA include midazolam for injection as an intranasal spray (indicated for sedation/anxiolysis/amnesia and anesthesia) and tablet forms of clonazepam (indicated for treatment for seizure disorders) and lorazepam (indicated for anxiety). In the European Union, buccal and intranasal midazolam are used for treating the indication of prolonged, acute convulsive seizures and rectal diazepam solution for the indication of epileptic and febrile convulsions; duration of effectiveness for these medications for the treatment of seizure clusters has not been established. This paper examines the literature context for understanding seizure clusters and their treatment and provides effectiveness, safety, and administration details for the three FDA-approved rescue therapies. Additionally, other medications that are used for rescue therapy in the USA and globally are discussed. Finally, the potential benefits of seizure action plans and candidates for their use are addressed. This paper is intended to provide details about the unique characteristics of rescue therapies for seizure clusters to help clarify appropriate treatment for individual patients. Graphical Abstract
- 15 February 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (2) , 125-140
Open AccessBenzodiazepines for the Treatment of Seizure Clusters
Patients with epilepsy may experience seizure clusters, which are described by the US Food and Drug Administration (FDA) as intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern. Untreated seizure clusters may increase the risk for status epilepticus, as well as decrease quality of life and increase burden on patients and care partners. Benzodiazepine therapies are the mainstay for acute treatment of seizure clusters and are often administered by nonmedical care partners outside a healthcare facility. Three rescue therapies are currently FDA-approved for this indication, with diazepam rectal gel being the first in 1997, for patients aged ≥ 2 years. Limitations of rectal administration (e.g., positioning and disrobing the patient, which may affect ease of use and social acceptability; interpatient variation in bioavailability) led to the investigation of the potential for nasal administration as an alternative. Midazolam nasal spray (MDS) was approved by the FDA in 2019 for patients aged ≥ 12 years and diazepam nasal spray (DNS) in 2020 for patients aged ≥ 6 years; these two intranasal therapies have differences in their formulations [e.g., organic solvents (MDS) vs. Intravail and vitamin E for absorption and solubility (DNS)], effectiveness (e.g., proportion of seizure clusters requiring only one dose), and safety profiles. In clinical studies, the proportion of seizure clusters for which only one dose of medication was used varied between the three approved rescue therapies with the highest single-dose rate for any time period for DNS; however, although studies for all three preparations enrolled patients with highly intractable epilepsy, inclusion and exclusion criteria varied, so the three cannot be directly compared. Treatments that have been used off-label for seizure clusters in the USA include midazolam for injection as an intranasal spray (indicated for sedation/anxiolysis/amnesia and anesthesia) and tablet forms of clonazepam (indicated for treatment for seizure disorders) and lorazepam (indicated for anxiety). In the European Union, buccal and intranasal midazolam are used for treating the indication of prolonged, acute convulsive seizures and rectal diazepam solution for the indication of epileptic and febrile convulsions; duration of effectiveness for these medications for the treatment of seizure clusters has not been established. This paper examines the literature context for understanding seizure clusters and their treatment and provides effectiveness, safety, and administration details for the three FDA-approved rescue therapies. Additionally, other medications that are used for rescue therapy in the USA and globally are discussed. Finally, the potential benefits of seizure action plans and candidates for their use are addressed. This paper is intended to provide details about the unique characteristics of rescue therapies for seizure clusters to help clarify appropriate treatment for individual patients. Graphical Abstract
- Open Access
- 22 August 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 147, 109369
Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study
- 22 August 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 147, 109369
Open AccessEffectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study
- Open Access
- 21 February 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 140, 109002
Written seizure action plans for adult patients with epilepsy: Distilling insights from emergency action plans for other chronic conditions
- 21 February 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 140, 109002
Open AccessWritten seizure action plans for adult patients with epilepsy: Distilling insights from emergency action plans for other chronic conditions
- Open Access
Seizure clusters: Practical aspects and clinical strategies to care for patients in the community
- 26 February 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 98, 87-94
Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study
- 26 February 2022
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 98, 87-94
Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study